The Business Times
SUBSCRIBERS

Amgen's new cancer drug treatment to cost US$178,000

Published Mon, Dec 22, 2014 · 09:50 PM
Share this article.

San Francisco

AMGEN Inc's leukaemia drug Blincyto will cost US$178,000 for a standard course of treatment, continuing a trend of high prices for immunotherapy, the newest wave of cancer treatments.

The price includes two US$89,000 cycles of therapy, the median duration of treatment for patients who responded in clinical studies, said Danielle Bertrand, a spokeswoman for Amgen, the second-biggest US biotechnology company. Each cycle consists of four weeks of treatment.

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to  t.me/BizTimes

Consumer & Healthcare

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

Get the latest coverage and full access to all BT premium content.

SUBSCRIBE NOW

Browse corporate subscription here